Opipramol
From Wikipedia, the free encyclopedia
 |
|
|
Opipramol
|
|
| Systematic (IUPAC) name | |
| 4-[3-(5H-Dibenz[b,f]azepin-5-yl)propyl]-1-piperazinethanol | |
| Identifiers | |
| CAS number | |
| ATC code | N06 |
| PubChem | |
| Chemical data | |
| Formula | C23H29N3O |
| Mol. mass | 363.496 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Opipramol (Opipramol-neuraxpharm, Insidon), is an anxiolytic primarily used in Germany. By structure it is a member of the family of tricyclic antidepressants, but lacks the mode of action as a neurotransmitter reuptake inhibitor common to other members of this family.[1] Unlike most tricyclic antidepressants, opipramol does not inhibit the reuptake of either serotonin or noradrenaline, but instead acts as a sigma antagonist.[2][3]
[edit] References
- ^ Opipramol ( Insidon ) for GAD : a placebo-controlled trial including an alprazolam (Xanax )-treated group
- ^ Müller WE, Siebert B, Holoubek G, Gentsch C. Neuropharmacology of the anxiolytic drug opipramol, a sigma site ligand. Pharmacopsychiatry. 2004 Nov;37 Suppl 3:S189-97. PMID 15547785
- ^ Volz HP, Stoll KD. Clinical trials with sigma ligands. Pharmacopsychiatry. 2004 Nov;37 Suppl 3:S214-20. PMID 15547788
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
